References
1. Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialties. Pantoprazole monograph. [ Available from: https://www.pharmacists.ca ].
2. Shaheen NJ, Falk GW, Iyer PG, Gerson LB, American College of G. ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus.Am J Gastroenterol. 2016;111(1):30-50; quiz 51.
3. Barkun AN, Almadi M, Kuipers EJ, et al. Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group. Ann Intern Med. 2019.
4. Therapeutics Initiative. A Systematic Review of the Comparative Effectiveness of Proton Pump Inhibitors for the Treatment of Adult Patients with Gastroesophageal Reflux Disease or Peptic Ulcer Disease. 2016. [ Available from: https://ti.ubc.ca/derp-ppi
5. Therapeutics Initiative. Comparative Effectiveness of Proton Pump Inhibitors. Therapeutics Letter 99. [ Available from: https://www.ti.ubc.ca/2016/06/28/99.
6. Kinoshita Y, Ishimura N, Ishihara S. Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use. J Neurogastroenterol Motil.2018;24(2):182-196.
7. Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. Ther Adv Drug Saf.2019;10:2042098618809927.
8. Makunts T, Cohen IV, Awdishu L, Abagyan R. Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. Sci Rep. 2019;9(1):2282.
9. Vaezi MF, Yang YX, Howden CW. Complications of Proton Pump Inhibitor Therapy. Gastroenterology. 2017;153(1):35-48.
10. Government of Canada. Advisories, Warnings and Recalls – Drugs and health products 2019 [Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/advisories-warnings-recalls.html.
11. Canadian Association of Gastroenterology, Choosing Wisely Canada. Gastroenterology–Five Things Physicians and Patients Should Question. Last updated: June 2017. https://choosingwiselycanada.org/gastroenterology/.
12. Farrell B, Pottie K, Thompson W, et al. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can Fam Physician. 2017;63(5):354-364.
13. Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 2019.
14. Boghossian TA, Rashid FJ, Thompson W, et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults.Cochrane Database Syst Rev. 2017;3:CD011969.
15. Therapeutics Initiative. Trends in utilization of proton pump inhibitors in British Columbia.Therapeutics Letter 118. [ Available from: https://www.ti.ubc.ca/2019/04/15/118.
16. Griebling TL. Re: American Geriatrics Society 2019 Updated AGS Beers Criteria(R) for Potentially Inappropriate Medication Use in Older Adults. J Urol. 2019;202(3):438.
17. Shiraev TP, Bullen A. Proton Pump Inhibitors and Cardiovascular Events: A Systematic Review. Heart Lung Circ. 2018;27(4):443-450.
18. Xie Y, Bowe B, Yan Y, Xian H, Li T, Al-Aly Z. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ. 2019;365:l1580.
19. Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology.2019;157(3):682-691 e682.
20. Charlot M, Grove EL, Hansen PR, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ. 2011;342:d2690.
21. Shiraev TP, Bullen A. Proton Pump Inhibitors and Cardiovascular Events: A Systematic Review. Heart Lung Circ. 2018;27(4):443-450.
22. Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS ONE. 2013;8(4):e62162.
23. Yasuda H, Matsuo Y, Sato Y, et al. Treatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy.World J Crit Care Med. 2015;4(1):40-46.
24. Yasuda H, Yamada M, Sawada S, et al. Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting.Intern Med. 2009;48(19):1725-1730.
25. Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018;3(4):231-241.
26. Hussain S, Singh A, Habib A, Najmi AK. Proton pump inhibitors use and risk of chronic kidney disease: Evidence-based meta-analysis of observational studies. Clinical Epidemiology and Global Health.2019;7(1):46-52.
27. Yepuri G, Sukhovershin R, Nazari-Shafti TZ, Petrascheck M, Ghebre YT, Cooke JP. Proton Pump Inhibitors Accelerate Endothelial Senescence.Circulation research. 2016;118(12):e36-42.
28. Corsonello A, Lattanzio F, Bustacchini S, et al. Adverse Events of Proton Pump Inhibitors: Potential Mechanisms. Curr Drug Metab.2018;19(2):142-154.
29. Sampathkumar K, Ramalingam R, Prabakar A, Abraham A. Acute interstitial nephritis due to proton pump inhibitors. Indian J Nephrol. 2013;23(4):304-307.
30. Yang Y, George KC, Shang WF, Zeng R, Ge SW, Xu G. Proton-pump inhibitors use, and risk of acute kidney injury: a meta-analysis of observational studies. Drug Des Devel Ther. 2017;11:1291-1299.
31. Lanas-Gimeno A, Hijos G, Lanas A. Proton pump inhibitors, adverse events and increased risk of mortality. Expert Opin Drug Saf.2019;18(11):1043-1053.
32. World Health Organization. Essential medicines and health products. Pharmacovigilance. Available from: https://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/.
33. Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. British journal of clinical pharmacology. 2011;72(6):905-908.
34. Hernan MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. American journal of epidemiology. 2016;183(8):758-764.
35. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. The New England journal of medicine. 2000;342(25):1878-1886.
36. Mulder R, Singh AB, Hamilton A, et al. The limitations of using randomised controlled trials as a basis for developing treatment guidelines. Evidence-based mental health. 2018;21(1):4-6.
37. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15(5):291-303.
38. Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open. 2017;7(6):e015735.